EXHIBIT 99.1

Utah Medical Products, Inc. Reports Financial Performance for Fourth Quarter and Year 2010
Salt Lake City, Utah - In the fourth calendar quarter (4Q) 2010 and year of 2010, Utah Medical Products, Inc.’s (Nasdaq: UTMD) changes in financial results compared to the same time period in the prior calendar year were as follows:
 
4Q
 (October – December)
Year
(January – December)
Sales:
(  4%)
(  3%)
Gross Profit:
(  5%)
(  4%)
Operating Income:
(  8%)
(  5%)
Net Income:
(  2%)
(  4%)
Earnings Per Share:
(  2%)
(  4%)

Profitability measures compared to the same time periods in the prior calendar year were as follows:
 
4Q10
4Q09
2010
2009
Gross Profit Margin (GPM):
52.9%
53.2%
52.6%
53.2%
Operating Profit Margin (OPM):
35.1%
36.6%
35.5%
36.4%
Net Profit Margin (NPM):
24.3%
23.8%
23.9%
24.1%

According to CEO Kevin Cornwell,
“Despite the decline of sales and eps in 2010, UTMD’s profitability demonstrated continued excellent overall performance. Domestic sales declined as U.S. hospitals have reduced utilization of physician-preference specialty devices. UTMD’s sales growth came in areas where it has its lowest profit margins, primarily internationally where UTMD sells through third party distributors.
The expansion of facilities in Utah and the consolidation of Oregon operations into Utah were completed in 2010. The full benefit of the consolidation will not be realized until 2011.

We invite shareholders to read UTMD’s SEC Form 10-K which will be published before March 16 to obtain more details regarding 2010 performance and management projections for 2011. UTMD’s focus remains on creating excellent long term shareholder value through providing highly reliable devices that help clinicians improve care and lower overall health care costs. We appreciate the continued confidence that our shareholders have demonstrated in the Company’s prospects for future success.”

Sales.
Compared to 4Q 2009, total 4Q 2010 international sales were $143,000 higher and total domestic sales were $428,000 lower.  For the year of 2010 compared to 2009, international sales were $399,000 or 5% higher while domestic sales were $1,194,000 or 6% lower.

Domestic sales include domestic direct sales (sales to U.S. end users) and domestic OEM sales (sales to other companies where products are components of their finished product offerings).  For 4Q 2010 compared to 4Q 2009, domestic direct sales were 9% lower and OEM sales were 15% lower.  For the year, domestic direct sales were down 6% as a result of lower utilization, reduced prices and group purchasing organization restrictions of clinician choice in U.S. hospitals. For the year, domestic OEM sales were down 7% as UTMD sales of components to other medical device firms were down about 11% and sales of molded parts to non-medical device firms, previously provided by UTMD’s Oregon facility, were up 7%.

 
 

 
 
U.S. dollar denominated sales of devices to international customers by UTMD’s Ireland facility were up 21% in 4Q 2010, but were down 1% for the year.  In Euro terms, UTMD Ltd 4Q 2010 sales were up 33% and were up 5% for the year.  The substantial difference was due to the fact that the average currency exchange rate in 2010 was 1.3223 USD/Euro compared to 1.4068 USD/Euro in 2009.  In other words, UTMD’s sales would have been $199,000 higher in 2010 with the same exchange rate as in the prior year.

Gross Profit.
UTMD did not achieve the marginal improvement in manufacturing costs it targeted for 2010.  A redundant Oregon operation was supported through May, and the transferred portion of molding to Utah did not move up the learning curve as quickly as expected.  A 9% reduction in inventories while sales also declined meant there was less absorption of fixed manufacturing overheads. Also, costs of raw materials from vendors increased more than expected.

In 2H 2010 after review of accounting principles, UTMD reallocated expenses of shipping products to customers previously included in cost of goods sold (manufacturing expense) to sales and marketing (operating expense).  The net impact of this accounting change was to increase the Company’s gross profit margin by about 0.6% for the year relative to what it would have been prior to the reallocation of shipping expenses. The following table illustrates the change:

              (in thousands)
4Q 2010
4Q 2009
2010
2009
CGS Expenses (prior to reallocation)
$ 2,995
$ 3,038
$ 12,052
$ 12,127
% of sales:
48.2%
46.8%
48.0%
46.8%
Reallocated shipping costs
$   (71)
 
$   (141)
 
CGS Expenses (as reported)
$ 2,924
$ 3,038
$ 11,911
$ 12,127
% of sales:
47.1%
46.8%
47.4%
46.8%

The reallocation of shipping expenses from CGS to operating expense does not affect reported operating income, earnings before taxes, profits after tax or earnings per share.

Operating Profit.
Because of lower sales, operating expenses in 2010 were 17.1% of sales compared to 16.8% of sales in 2009 even though total 2010 operating expenses were $70,000 lower than in 2009.  R&D (research and development) expenses were 1.6% of sales compared to 1.4% in 2009.  S&M (sales and marketing) expenses were 6.1% of sales in both years. G&A (general and administrative) expenses were 9.4% of sales in 2010 compared to 9.3% in 2009.  The OPM in 2010 was 35.5% of sales compared to 36.4% in 2009 primarily because of the lower 2010 GPM (higher manufacturing costs relative to sales).

Net Profit.
Lower non-operating income by $29,000 compared to the previous year was offset by a lower income tax provision rate. The lower non-operating income resulted from low interest rates on UTMD’s excess cash deposits. The consolidated income tax rate for the year was 33.5% compared to 34.7% in 2009.  The lower tax provision rate was due mainly to a larger portion of consolidated taxable income generated in Ireland at much lower income tax rates than in the U.S. UTMD’s NPM for 2010 of 23.94% closely met its previously announced target of 24% of sales.  In 2009, the NPM was 24.1%.

 
 

 

Earnings Per Share (EPS).
Outstanding shares at the end of 2010 were 3,618,800. The number of shares used for calculating earnings per share was higher than ending shares because of a time-weighted calculation of average outstanding shares plus dilution from unexercised employee and director options.  The total number of outstanding unexercised employee and outside director options at December 31, 2010 was 216,900 shares at an average exercise price of $24.75/ share, including shares awarded but not vested. This compares to 241,700 unexercised option shares outstanding at the end of 2009. UTMD=s dilution from unexercised option shares added to actual weighted average outstanding shares for purposes of calculating EPS was 24,900 in 4Q 2010 compared to 36,700 in 4Q 2009, and 22,500 in 2010 compared to 22,300 in 2009.  UTMD’s dividends paid to shareholders during 2010 were 101% of EPS.

During 2010, UTMD repurchased only 17,600 of its shares in the open market at an average cost of $24.98 per share. No shares were repurchased during 4Q 2010. The Company retains the financial ability for repurchasing its shares when they seem undervalued. The closing share price at the end of 2010 was $26.88, down 8% from $29.32 at the end of 2009.

Highlights regarding changes in UTMD’s Balance Sheet during 2010 include:
1)  Cash and investments balances decreased only by $0.7 million after the Company spent $6.0 million making dividend payments to shareholders and $0.4 million repurchasing its shares in the open market.
2)  The Ireland loan balance declined $0.5 million or 33% in U.S. Dollar terms. The loan obligation is held in EURO currency. In EURO terms, 27% of the 12-31-09 loan balance was repaid in 2010.
3)  In another difficult year for the liquidity of customers, UTMD incurred less than $9 in bad debt write-offs, and simultaneously reduced its year-end aged over-90 days A/R balances to 1.5% of total receivables.
4)  UTMD was able to reduce inventories by 9% even though sales declined only by 3%.

Financial ratios as of December 31, 2010 which may be of interest to shareholders follow:
1)  Current Ratio = 13.2
2)  Days in Receivables (based on 4Q sales activity) = 42
3)  Average Inventory Turns (based on 2010 CGS) = 3.7
4)  2010 ROE = 16% (prior to payment of dividends)

Investors are cautioned that this press release contains forward looking statements and that actual events may differ from those projected.  Risk factors that could cause results to differ materially from those projected include market acceptance of products, timing of regulatory approval of new products, regulatory intervention in current operations, government health care “reforms”, the Company’s ability to efficiently manufacture, market, and sell its products, among other factors that have been and will be outlined in UTMD=s public disclosure filings with the SEC.

Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures, assembles and markets a broad range of disposable and reusable specialty medical devices designed for better health outcomes for patients and their care-providers.  For more information about Utah Medical Products, Inc., visit UTMD=s website at www.utahmed.com.

 
 

 

Utah Medical Products, Inc.

INCOME STATEMENT, Fourth Quarter (3 months ended December 31)
(in thousands except earnings per share):
 
4Q 2010
4Q 2009
Percent Change
Net Sales
$6,208
$6,493
(4.4%)
Gross Profit
3,284
3,455
(4.9%)
Operating Income
2,181
2,376
(8.2%)
Income Before Tax
2,233
2,376
(6.0%)
Net Income
1,509
1,547
(2.5%)
Earnings Per Share
$0.414
$0.424
(2.3%)
Shares Outstanding (diluted)
3,642
3,647
 

INCOME STATEMENT, Year (12 months ended December 31)
(in thousands except earnings per share):
 
 2010
 2009
Percent Change
Net Sales
$25,121
$25,916
(3.1%)
Gross Profit
13,209
13,789
(4.2%)
Operating Income
8,922
9,432
(5.4%)
Income Before Tax
9,041
9,580
(5.6%)
Net Income
6,014
6,258
(3.9%)
Earnings Per Share
$1.651
$1.724
(4.2%)
Shares Outstanding (diluted)
3,643
3,630
 


BALANCE SHEET
(in thousands)
 
(audited)
DEC 31, 2010
(unaudited)
SEP 30, 2010
(audited)
DEC 31, 2009
Assets
     
  Cash & Investments
$18,536
$21,351
$19,255
  Receivables, Net
3,163
2,866
3,157
  Inventories
3,097
3,270
3,407
 Other Current Assets
346
474
414
     Total Current Assets
25,142
27,961
26,233
Property & Equipment, Net
8,750
8,892
8,133
Intangible Assets, Net
7,346
7,357
7,388
        Total Assets
$41,238
$44,210
$41,754
Liabilities & Shareholders’ Equity
     
  A/P & Accrued Liabilities
$  1,688
$  2,423
$  1,497
  Current Portion of Note Payable
215
231
264
     Total Current Liabilities
   1,903
  2,654
  1,761
Note Payable (excluding current portion)
909
1,037
1,403
Deferred Income Taxes
634
741
609
Stockholders’ Equity
37,792
39,778
37,981
        Total Liabilities & Shareholders’ Equity
$41,238
$44,210
$41,754

 



The following information was filed by Utah Medical Products Inc (UTMD) on Thursday, January 27, 2011 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Utah Medical Products Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Utah Medical Products Inc.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account